Prostate Cancer Topics
The On-Topic Netowork

Prostate Cancer > Antagonist


Antagonist
Antagonist
Antagonist
Antagonist
Antagonist

The following information is about Antagonist.

Antagonist Defined

A drug that has an opposite reaction or competes for the same thing

This definition is in context to Prostate Cancer. See more contextual defintions for Antagonist.


Navigation: [ 1 2 Next ]

Editors Memo

Published September 5, 2008, 6:34 am, BioMechanics

Does dark matter cause ACL injuries? I see two types of dark matter on our radar. One is quite exciting, at least to this former astronomy major, and one is potentially catastrophic.

Full Story


Pain Management

Published September 4, 2008, 2:18 pm, BioMechanics

Throughout history, various forms of morphine have been the most effective medications in relieving pain. Opioid analgesics—the natural, semisynthetic, and synthetic derivatives of morphine—are used routinely in the management of acute musculoskeletal pain.

Full Story


Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira

Published September 4, 2008, 4:00 am, PR Newswire via Yahoo! Finance

Human Genome Sciences, Inc. today announced that it has entered into an exclusive agreement with Hospira, Inc., for manufacturing process development and commercial supply of select Hospira biopharmaceutical products.

Full Story


Human Genome Sciences Reports Initial Results Of Randomized Phase 2 Trial Of HGS-ETR1 In Combination With Bortezomib ...

Published September 4, 2008, 3:09 am, Medical News Today

Human Genome Sciences, Inc. (Nasdaq: HGSI) reported initial topline results from an ongoing randomized Phase 2 clinical trial of its TRAIL receptor antibody HGS-ETR1 (mapatumumab) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma.

Full Story


Curis Announces Dosing Of First Patient In Phase I Clinical Trial Of CUDC-101

Published September 4, 2008, 12:20 am, DrugDiscoveryOnline

Curis, Inc.a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment today announced that the first patient has been treated in a Phase I clinical trial of CUDC-101, a first-in-class small molecule drug candidate that has been designed as an inhibitor of epidermal growth factor receptor

Full Story


Research and Markets: A Competitor Analysis Report of Toll-Like Receptor (TLR) Agonists & Antagonists

Published September 3, 2008, 8:08 am, Centre Daily Times

Research and Markets (http://www.researchandmarkets.com/research/4af4b3/competitor_analysi) has announced the addition of the "Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists" report to their offering.

Full Story


Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib ...

Published September 2, 2008, 1:05 pm, PR Newswire via Yahoo! Finance

Human Genome Sciences, Inc. today reported initial topline results from an ongoing randomized Phase 2 clinical trial of its TRAIL receptor antibody HGS-ETR1 in combination with bortezomib in patients with advanced multiple myeloma.

Full Story


Human Genome Sciences Completes Enrollment In Second Phase 3 Lymphostat-B(R) Trial

Published September 2, 2008, 5:11 am, Medical News Today

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced it has completed enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials of LymphoStat-B® (belimumab) in patients with active systemic lupus erythematosus (SLE).

Full Story


Curis Announces Nature Publication Elucidating A Paracrine Mechanism Of Action In Hedgehog-Expressing Tumors

Published August 31, 2008, 3:09 am, Medical News Today

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment, announced the publication of preclinical data in Nature that support the premise that Hedgehog proteins play an important role in supporting tumor growth in Hedgehog-expressing solid tumors through a paracrine mechanism of action.

Full Story


Genentech to initiate phase-II trial of GDC-0449 for ovarian cancer

Published August 30, 2008, 1:52 am, PharmaBiz

Curis, Inc, a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, announced that its collaborator Genentech, Inc has indicated that it expects to initiate a phase-II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog antagonist, as a maintenance therapy for ovarian cancer patients in second or third ...

Full Story


Navigation: [ 1 2 Next ]

Are you looking for additional Prostate Cancer > Antagonist news? Try our new "Antagonist News Focus" area.

Off-site Antagonist Links, User Submitted

The following links have been collected through user bookmark submission in the Antagonist category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Thu Sep 4

Mon Sep 1

If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Antagonist. If you would like to find related tags we recommend Tag Patterns > Antagonist

Off-site Antagonist Research Links

If you still need additional information on Antagonist then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Prostate Cancer

If you know the Prostate Cancer Term Name use the links below to quickly jump to your desired focus.



Bookmark Us

The On Topic Network

This website is part of The On Topic Network.

Thank You

Prostate-Cancer.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.

Best Viewed With

License

Creative Commons License This work is licensed under Creative Commons.




Powered by Odin Assemble 2.5a